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CASE PRESENTATION
A 59-year-old Caucasian woman presented with
a 5-month history of worsening renal insufficiency,
proteinuria, and increasing leg edema. Serum creatinine on
admission was 3.3 mg/100 ml (estimated glomerular
filtration rate 15 ml/min). Baseline serum creatinine
7 months previously was 0.9 mg/100 ml. There was no
history of diabetes or hypertension and no family history of
renal disease. The patient was diagnosed with metastatic
mammary ductal adenocarcinoma in 1993 and underwent
radical mastectomy, radiation therapy, and several courses
of chemotherapy. Her regular medications included
pamidronate (90 mg monthly for 5 years) and abraxane
(albumin-bound paclitaxel) 120 mg every other week.
The patient was started on bevacizumab (anti-vascular
endothelial growth factor (VEGF) antibody) 7 months
previously (400 mg every other week, increasing to
800 mg every other week after 2 months). However,
approximately 3 months after starting anti-VEGF therapy,
she developed new onset of leg edema, shortness of
breath, generalized weakness, and hypertension (blood
pressure 164/83 mm Hg). Serum creatinine was noted to
be elevated (1.9 mg/100 ml, normal (N) o1.2 mg/100 ml).
Urinalysis was not performed. Bevacizumab was
discontinued and the patient was started on furosemide
40 mg daily. Chemotherapy was switched from abraxane
to 5-fluoruracil 2 g p.o. b.i.d. Over the next 4 months,
serum creatinine increased to 3.2 mg/100 ml and the
patient was referred for nephrology evaluation. On
physical examination, blood pressure remained well
controlled (average 140/80 mm Hg). There was mild
(1þ ) peripheral edema, but no rash or other physical
abnormality was noted. Urinalysis showed 4þ protein
and no cells. A 24-h urine collection contained 3.6 g
protein. Serum albumin was decreased (2.9 g/100 ml).
Serum lactate dehydrogenase was slightly elevated
(226 IU/l, N 122–220 IU/l), but all other hematologic studies
were within the normal range, including hematocrit
(37.2%), white blood cell count (6.3 103/ml), platelet
count (230 103/ml), haptoglobin (283 mg/100 ml,
N 20–300 mg/100 ml). No schistocytes were seen on
peripheral smear. Serologic work revealed negative
antinuclear antibody, hepatitis B surface antigen, and
hepatitis C virus antibodies. Kidney size was within
normal limits and ultrasound showed no evidence of
hydronephrosis or obstruction.
A renal biopsy was performed to evaluate the cause of
nephrotic range proteinuria and worsening renal function.
RENAL BIOPSY
Light microscopic examination revealed eight glomeruli,
none of which were globally sclerotic. Glomeruli were mildly
enlarged and showed diffuse duplication of glomerular
basement membranes, with endothelial swelling, widening
of the subendothelial space, and rare cellular interposition
(Figure 1). No fibrin thrombi were seen. Three glomeruli
showed prominent hypertrophy of podocytes containing
cytoplasmic protein droplets, with formation of pseudo-
crescents and segmental collapse of underlying glomerular
basement membranes (Figure 2). Proximal tubules showed
patchy degenerative and regenerative changes including loss
of apical brush border, nuclear enlargement, and prominent
nucleoli. Tubular atrophy and interstitial fibrosis involved
approximately 40% of the cortical area, accompanied by a
mild patchy interstitial mononuclear inflammatory cell
infiltrate. Arterial vessels showed mild intimal fibrosis and
medial sclerosis, with no evidence of vasculitis or intraarterial
thrombi.
Immunofluorescence microscopy showed segmental finely
granular glomerular capillary wall staining for IgA, kappa,
and lambda (all 1–2þ intensity), with negativity for IgG,
IgM, C3, C1, fibrinogen, and albumin (Figure 3). Electron
microscopy revealed diffuse subendothelial accumulation of
electron lucent, flocculent material with small intermingled
electron densities. (Figure 4). However, no discrete immune-
type electron-dense deposits or endothelial tubuloreticular
inclusions were seen. Podocytes showed approximately 60%
foot process effacement.
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DIAGNOSIS
Glomerular thrombotic microangiopathy with focal collap-
sing glomerulopathy and capillary wall IgA deposits (asso-
ciated with bevacizumab and pamidronate).
CLINICAL FOLLOW-UP
Bevacizumab had been discontinued 4 months before
renal biopsy, and pamidronate was discontinued after renal
biopsy. The patient was started on enalapril 5 mg b.i.d. and
lipitor 40 mg daily, and her diuretic regimen was optimized
with lasix 40 mg b.i.d. and metolazone 2.5 mg p.o. b.i.d.,
with adjustment of diuretics dose based on close clinical
evaluation. At 6 months follow-up, serum creatinine had
decreased from 4.8 mg/100 ml to 1.7 mg/100 ml, and there was
partial remission of nephrotic syndrome. Urinalysis showed
2þ protein and no cells. The 24 h urine protein was 990 mg,
lipid profile was normal, and serum albumin was 3.4 g/100 ml.
Blood pressure was well controlled (120/60 mm Hg), but
there was persistent 1þ peripheral edema.
DISCUSSION
Anti-angiogenic drugs that inhibit the action of vascular
endothelial growth factor (VEGF) have shown clinical
efficacy in the treatment of metastatic carcinoma, including
lung, colorectal, breast, and renal cell carcinoma.1 These
agents inhibit VEGF by binding and blocking of VEGF
receptor (for example, Bevacizumab and VEGF Trap) or by
inhibition of intracellular receptor tyrosine kinase signaling
Figure 2 | Glomerulus shows capillary collapse and
hyperplasia of overlying epithelial cells containing prominent
cytoplasmic protein droplets (periodic acid Schiff reaction;
original magnification  600).
Figure 3 | Immunofluorescence microscopy shows global
finely granular peripheral capillary wall staining for IgA
(original magnification  400).
Figure 1 | Glomerulus showing narrow duplication of
glomerular basement membranes with rare cellular
interposition, consistent with subacute/chronic thrombotic
microangiopathy (periodic acid Schiff reaction; original
magnification  400).
Figure 4 | Electron microscopy shows marked subendothelial
accumulation of ill-defined electron lucent material and no
immune-type electron dense deposits (original magnification
 30,000).
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(for example, sunitnib and sorafenib).1 Anti-VEGF agents are
generally well tolerated, but hypertension and asymptomatic
proteinuria are common dose-related side-effects that
frequently occur together.2,3 The incidence of hypertension
in bevacizumab-treated cancer patients ranges from 2.7 to
35.9%.2 In most patients, hypertension can be managed with
standard oral antihypertensive agents and does not require
anti-VEGF drug cessation.3 The incidence of proteinuria
ranges from 21% in non-small lung cancer patients up to
63% of those with renal cell carcinoma.4,5 Proteinuria is
usually mild and asymptomatic but heavy proteinuria
(43.5 g/day) has been described in up to 6.5% of renal cell
carcinoma patients.5 In renal cell carcinoma patients, both
hypertension and proteinuria uniformly decreased after
cessation of anti-VEGF therapy.5
The renal pathological findings in bevacizumab-associated
heavy proteinuria include four cases of thrombotic micro-
angiopathy6–8 and one case each of cryoglobulinemic
glomerulonephritis,9 collapsing glomerulopathy,10 and
immune complex-associated focal proliferative glomerulone-
phritis11 (Table 1). We describe the first report of bevacizu-
mab-associated heavy proteinuria in a patient with metastatic
breast cancer. Pathological findings in this case also showed
features of collapsing glomerulopathy, which probably
reflects podocyte toxicity due to concomitant pamidronate
therapy.12
Frangie et al.6 reported a case of bevacizumab-associated
thrombotic microangiopathy in a patient with metastatic
renal cell carcinoma. The patient, a 70-year-old white
man, had baseline renal insufficiency following tumor
nephrectomy, but no proteinuria. He initially received
interferon-a (IFN-a), which was discontinued after 7 months
due to the development of severe hypertension, without
evidence of proteinuria. One month later, bevacizumab was
started at 2-weekly intervals. Following the second injection
of bevacizumab, the patient developed severe hypertension,
nephrotic syndrome, renal failure, and evidence of hemolytic
uremic syndrome (haptoglobin o0.08 mg/l, lactic dehydro-
genase 389 IU/l, hemoglobin 102 g/l, and thrombocytopenia),
with renal biopsy findings of glomerular thrombotic micro-
angiopathy. Renal function returned to baseline following
discontinuation of bevacizumab, but heavy proteinuria
persisted. A subsequent course of sunitinib (another anti-
VEGF agent) was complicated by recurrence of hemolytic
uremic syndrome, which responded to discontinuation of
treatment and plasma exchange.
Izzedine et al.7 described one case of glomerular
thrombotic microangiopathy in patients receiving anti-
VEGF therapy. The patient was a 59-year-old woman
with chemoresistant metastatic ovarian cancer who received
two intravenous infusions of VEGF Trap 4.0 mg/kg and
standard doses of leucovorin/5-fluorouracil/irinotecan at
2-week intervals. Baseline renal function and blood pressure
were normal. One week after starting therapy, hypertension
(170/90 mm Hg) and mild proteinuria (0.45 g/day) were
detected. Following the second treatment, blood pressure
increased to 190/100 mm Hg and nephrotic syndrome
developed, with microscopic hematuria and normal renal
function. Renal biopsy revealed glomerular thrombotic
microangiopathy. Following discontinuation of anti-VEGF
and LV5FU2-CPT-11, the patient was treated with anti-
hypertensive medications, corticosteroids, and plasma-
pheresis, leading to partial recovery 2 months later (blood
pressure 100/80 mm Hg, proteinuria 0.3 g/l, serum creatinine
1.4 mg/100 ml).
Roncone et al.8 described a 58-year-old white male with
metastatic renal cell carcinoma who developed new-onset
proteinuria, eventually reaching 6.958 g/day, beginning
9 months after starting treatment with bevacizumab and
IFN-a2b, accompanied by a rise in serum creatinine. Despite
discontinuation of IFN-a2b and bevacizumab, proteinuria
and renal insufficiency persisted. Proteinuria was unrespon-
sive to angiotensin receptor blockers and angiotensin-
converting enxyme inhibitor therapy. At the time of biopsy,
Table 1 | Summary of biopsy-documented glomerular disease in anti-VEGF-treated patients
Ref.
Anti-VEGF
agent Other therapy Onset Proteinuria
Peak BP
(mm Hg)
Peak sCr
(mg/100 ml)
Extrarenal
signs Biopsy findings
Follow-up
(months)
6 Bevacizumab IFN-a (d/c) 2 weeks 6.1b 210/130 GFR 23 ml/min HUS Glomerular TMA Persistent
proteinuria (2)
7 VEGF Trap LV5FU2/
Capecitabine
1 week 16.6 g/l 190/100 Na None Glomerular TMA Persistent
proteinuria (2)
8 Bevacizumab IFN-a 9 months 6.985 g/day 157/100 1.59 None Glomerular TMA Persistent
proteinuria (7)
8 Bevacizumab IFN-a 7 months 1–2+ N/A N/A None Glomerular TMA N/A
9 Bevacizumab Carboplatin/
paclitaxel
N/A ‘Nephrotic
syndrome’
N/A N/A N/A Cryoglobulinemic GN N/A
10 Bevacizumab Capecitabine/
pamidronate
N/A ‘Nephrotic
syndrome’
N/A N/A N/A Collapsing glomerulopathy N/A
11 Bevacizumab Gemcitabine/
capecitabine/ RTx
1 months 9.6 g/day 198/85 N/A None Focal proliferative immune
complex GN
Persistent
proteinuria (9)
This case Bevacizumab Paclitaxel/
pamidronate
3 months 3.6 g/day 164/83 3.2 None Glomerular TMA/collapsing
glomerulopathy
Persistent
proteinuria (6)
BP, blood pressure; d/c, IFNa was discontinued before starting anti-VEGF therapy; GFR, glomerular filtration rate; HUS, hemolytic uremic syndrome; IFN-a, interferon-alpha;
LV5FU2-CPT11, leucovorin5-fluorouracil/capecitabine; N, normal; N/A, not available; RTx, radiation therapy; sCr, serum creatinine; TMA, thrombotic microangiopathy;
aRenal insufficiency at baseline.
bUrinary albumin mg/creatinine mg.
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blood pressure was 142/80 mm Hg. A renal biopsy performed
3 months after cessation of therapy revealed thrombotic
microangiopathy and mesangial and capillary wall IgA
deposits, findings that had not been identified in the original
tumor nephrectomy specimen.8 The patient had persistent
proteinuria (1.89 g/day) 7 months following discontinuation
of bevacizumab, and serum creatinine had returned to
baseline levels. In the absence of hematuria or typical
mesangial deposits, the authors felt that these pathological
findings were not diagnostic of IgA nephropathy.8 The same
authors also described a second case of thrombotic micro-
angiopathy in a patient who received bevacizumab plus
IFN-a2b for 9 months before undergoing partial nephrec-
tomy for recurrent renal cell carcinoma.8 This individual
developed new onset of mild proteinuria (1–2þ on dipstick)
following 7 months of therapy. Examination of the non-
neoplastic nephrectomy tissue revealed features of throm-
botic microangiopathy, without immune complex deposits
by immunofluorescence or electron microscopy. Follow-up
data were not provided.
The pathogenesis of proteinuria in patients receiving anti-
VEGF therapy likely relates to perturbation of podocyte-
endothelial VEGF axis signaling.13 VEGF is constitutively
expressed by podocytes, and VEGF receptors are present on
normal glomerular capillary endothelial cells.13 Experimental
evidence indicates that VEGF plays an essential role in
glomerular development, endothelial maintenance, and
endothelial repair following injury.14–16 Podocyte-specific
heterozygosity for VEGF-A produces proteinuria and endo-
theliosis, whereas the homozygous deletion causes failure of
glomerular capillary development.15 Conversely, podocyte-
specific overexpression of VEGF leads to collapsing glome-
rulopathy.15 Further evidence for the role of VEGF in
maintaining normal glomerular function is the observation
that elevated circulating levels of fms-like tyrosine kinase 1
(sFlt1), a soluble inhibitor of VEGF receptor, predicts the
development of preeclampsia, a disorder characterized by
proteinuria and glomerular endotheliosis.17 Proteinuria in
anti-VEGF-treated patients is dose dependent2 and correlates
with the presence of hypertension,2,3 suggesting a role for
endothelial dysfunction and other hemodynamic cofactors,
particularly in the majority of cases that show only mild
proteinuria.10 The relatively high incidence of proteinuria in
bevacizumab-treated renal cell carcinoma patients5 suggests
a possible ancillary role for adaptive hyperfiltration response
to reduced nephron number, due to either nephrectomy
or replacement by tumor.
Severe renal side-effects are uncommon with anti-VEGF
therapy but have been described with several related
therapeutic agents, including bevacizumab, sunitinib, and
VEGF Trap, suggesting a drug class effect.3 In cases with
biopsy-proven glomerular disease (Table 1), renal symptoms
usually developed early (following the second or third dose)
and were characterized by nephrotic syndrome and hyper-
tension. Although renal function data are not available for
most cases, at least some patients also develop renal
insufficiency.6,8 In most cases, renal biopsy showed features
of subacute glomerular thrombotic microangiopathy, pre-
dominantly endotheliosis and membranoproliferative
changes, consistent with a central role for endothelial
dysfunction related to inhibition of normal VEGF signaling.
Of note, these findings are similar to the pathology of
preeclampsia/eclampsia. Only one patient presented with
extrarenal signs of microangiopathic hemolytic anemia in
addition to nephrotic syndrome,6 suggesting that glomerular
endothelium may be particularly susceptible to the toxicity of
anti-VEGF agents. The relative rarity of thrombotic micro-
angiopathy in anti-VEGF-treated patients suggests a role for
additional pathogenetic factors, which may include hyper-
tensive injury and concomitant use of other nephrotoxic
agents, such as IFN-a, gemcitabine, and pamidronate.10
In addition to thrombotic microangiopathy, our case also
showed features of collapsing glomerulopathy, which likely
contributed to the severity of proteinuria. Although we
cannot entirely exclude that collapsing glomerulopathy in
this case was secondary to severe endovascular injury, as has
been rarely described in renal allografts18 and in sickle-cell
nephropathy,19 it is worth noting that the only other patient
who developed collapsing glomerulopathy during anti-VEGF
therapy (without thrombotic microangiopathy) was also
receiving pamidronate.10 Most cases of pamidronate-induced
collapsing glomerulopathy have been linked to the use of
supratherapeutic drug doses12 but an increased incidence of
subnephrotic proteinuria was noted in metastatic breast
carcinoma patients receiving concurrent bevacizumab and
pamidronate compared with those receiving bevacizumab
alone (33.9 vs 18.5%).10 Given the close anatomical
proximity and functional interdependence of glomerular
endothelial and epithelial cells, it is reasonable to speculate
that combined use of bevacizumab and pamidronate may
synergistically predispose to glomerular toxicity, even with
conventional doses of pamidronate. By causing direct
podocyte toxicity, pamidronate could inhibit endogenous
VEGF synthesis by injured podocytes, thereby augmenting
local VEGF deficiency.
Similar to the case report of Roncone et al.,7,8 our case
also showed capillary wall IgA staining, but our case did not
show discrete immune-type electron-dense deposits by
electron microscopy (Figure 4). Moreover, neither of these
two patients had hematuria, arguing against co-existing IgA
nephropathy. bevacizumab is a recombinant humanized
murine monoclonal IgG1 antibody; hence, the IgA staining
cannot be attributed to detection of the drug molecule. It is
possible that nonspecific ‘trapping’ of IgA may be occurring
within damaged capillary walls; however, this finding is not
generally observed in other causes of thrombotic micro-
angiopathy. Although the significance of this finding is
uncertain, its occurrence in two cases associated with
bevacizumab therapy is intriguing and suggests a possible
pathogenetic relationship.
In summary, we describe the first biopsy-proven case of
glomerular thrombotic microangiopathy occurring in the
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setting of bevacizumab therapy for metastatic breast
carcinoma. The finding of coexistent collapsing glomerulo-
pathy in this case is probably related to concomitant
pamidronate therapy, which may have potentiated local
VEGF insufficiency at the level of the glomerulus. This is the
second report of bevacizumab-related glomerular thrombotic
microangiopathy with the peculiar finding of capillary wall
IgA staining. Although rare, significant glomerular disease,
featuring nephrotic syndrome and hypertension, is now a
well-described complication of anti-VEGF therapy. Conco-
mitant exposure to other chemotherapeutic agents may
predispose the glomerular endothelium to injury. Heightened
clinical awareness of this potential drug toxicity is important
in anti-VEGF-treated patients who develop new onset of
proteinuria, hypertension, and renal insufficiency, as these
patients generally do not show hematological features of
hemolytic uremic syndrome. Renal biopsy findings predo-
minantly show endotheliosis and basement membrane
duplication, without overt fibrin glomerular thrombi in
most cases, similar to the pathology of preeclampsia/
eclampsia. Both proteinuria and hypertension may improve
following discontinuation of anti-VEGF therapy and institu-
tion of anti-hypertensive therapy.
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